

Prostate Cancer Quality Performance Indicators

Patients diagnosed from July 2018 to June 2021

An Official Statistics release for Scotland

Publication date: 13 December 2022

About this release

This release by Public Health Scotland (PHS) presents performance against the National Prostate Cancer Quality Performance Indicators (QPIs) in the Cancer QPIs dashboard held within the Scottish Cancer Registry and Intelligence Service (SCRIS).

Main points

- There were 3,543 men diagnosed with Prostate Cancer in Scotland from July 2020 to June 2021. This was similar to the 3,530 diagnosed from July 2019 to June 2020 but a substantial decrease from July 2018 to June 2019 where 3,741 men were diagnosed.
- At Scotland level for July 2020 to June 2021, the target was met for five of the 12 indicators.

QPI	Target	18/19	19/20	20/21	
QPI 2: Radiological Staging	95%		97.2	98.7	Target met
QPI 2(ii): Radiological Staging Years 2:7	95%	96.2			Target met
QPI 4(i): Multi-Disciplinary Team (MDT) Meeting Non-metastatic	95%	94.6	95.7	96.4	Target met
QPI 4(ii): Multi-Disciplinary Team (MDT) Meeting Metastatic	95%	91.4	91.9	95.1	Target met
QPI 5: Surgical Margins	<20%	15.0	21.1	19.6	Target not met
QPI 7(i): Hormone Therapy	95%	89.4	91.6	92.0	Target met
QPI 7(ii): Hormone Therapy and Docetaxel Chemotherapy	40%	23.2	12.8	2.0	Target not met
QPI 8: Post Surgical Incontinence	50%		20.6	26.0	Target not met
QPI 11: Management of Active Surveillance	95%		39.1	45.3	Target not met
QPI 14(i): Diagnostic Pre-biopsy MRI	95%		91.9	97.1	Target met
QPI 14(ii): Diagnostic Pre-biopsy MRI with PI-RADS/Likert grading	95%		74.8	77.0	Target not met
QPI 15(i): Low Burden Metastatic Disease	95%		73.2	75.4	Target not met
QPI 15(ii): Low Burden Metastatic Disease with Radiotherapy	60%		54.9	52.8	Target not met

Information is available on performance against **QPI 6 Volume of Cases per Surgeon**

- Some of the QPI targets have proved challenging to achieve over the three years (QPIs relating to Hormone Therapy (QPI 7), Post Surgical Incontinence (QPI 8), Management of Active Surveillance (QPI 11) and Low Burden Metastatic Disease (QPI 15)).
- Regarding QPI 7(ii), in April 2020, the National Cancer Medicines Advisory Group approved the routine off-label use of oral Abiraterone in low risk newly diagnosed metastatic hormone sensitive prostate cancer patients who would otherwise be offered Docetaxel. This contributed to the substantial decline in numbers of patients receiving Docetaxel during April to June 2020 and all of 2020/21.
- It is reassuring however that the QPI relating to Radiological Staging (QPI 2) was met nationally throughout the three years. Also encouraging is that an improvement in the most recent 2020/21 results can be seen in the majority of QPIs compared to previous years.
- Following a national formal review of Prostate QPIs in October 2022, there will be some changes made to existing QPIs in future years which should result in improvements.

Background

National cancer quality performance indicators have been developed to support continuous quality improvement in cancer care (**CEL 06 2012**). NHS Boards are required to report these indicators against a clinically agreed indicator specific target as part of the mandatory national cancer quality programme. They have been developed collaboratively by **North Cancer Alliance, South East Scotland Cancer Network, West of Scotland Cancer Network, Healthcare Improvement Scotland** and PHS.

Contact

Garry Hecht | Principal Information Analyst | phs.cancerstats@phs.scot

Angus Morton | Information Analyst | phs.cancerstats@phs.scot

For all media enquiries please email phs.comms@phs.scot or call 0131 275 6105.

Further information

- The Cancer QPIs dashboard is restricted and may be accessed with permission via <https://useraccess.nhsnss.scot.nhs.uk>
- Network Reports on Prostate QPIs: **NCA, SCAN** and **WoSCAN**. These reports contain additional commentary on performance against the QPIs.
- QPI Definitions and updates on **Prostate Cancer indicators**
- PHS QPI **Publications**

The next release of this publication will be December 2025.

Other formats of this publication are available on request by calling 0131 314 5300 or emailing phs.otherformats@phs.scot.

PHS and Official Statistics

Public Health Scotland (PHS) is the principal and authoritative source of statistics on health and care services in Scotland. PHS is designated by legislation as a producer of 'Official Statistics'. Our official statistics publications are produced to a high professional standard and comply with the Code of Practice for Statistics. **Further information about our statistics.**